Here are a few brief analogies for Autonomix Medical (AMIX):

• A significantly more precise **Boston Scientific** or **Medtronic** for neural sensing and treatment.

• The **Intuitive Surgical** of ultra-precise nerve mapping and intervention.

• Catheter-based Neural Sensing System: A microchip-enabled catheter array designed for highly sensitive detection and differentiation of neural signals.
• Transvascular Ablation Treatment System: A medical device intended for targeted nerve ablation to treat conditions such as pain associated with pancreatic cancer.
• Integrated Neurological Sensing and Treatment Platform: A comprehensive technology platform combining high-sensitivity neural sensing with targeted treatment capabilities for various nerve-related disorders.

Brad Hauser President and Chief Executive Officer

Mr. Hauser was appointed President and Chief Executive Officer in June 2024. He is a globally renowned medical technology innovation leader with over 20 years of experience. Mr. Hauser previously served as Chief Operating Officer at Beauty Health and as President and Chief Executive Officer at Soliton, where he led the RESONIC brand from early commercial launch through its acquisition by Allergan Aesthetics, an AbbVie company, for $550 million in 2021. His career highlights include pivotal roles in companies such as Soliton, Inc., ZELTIQ Aesthetics, and Reliant Technologies, contributing to their successful acquisitions. He has also been an officer of four public companies.

Trent N. Smith Chief Financial Officer

Mr. Smith joined Autonomix Medical as Chief Financial Officer in July 2023. He is a seasoned Life Sciences and MedTech financial executive with extensive experience in providing financial and business leadership to private and public companies. Prior to joining Autonomix, from June 2018 to September 2022, Mr. Smith served as the Corporate Controller and Vice-President of Soliton, Inc., a medical device company that was acquired by AbbVie, Inc. in December 2021 for approximately $550 Million. Mr. Smith is a Certified Public Accountant (CPA).

Walter V. Klemp Executive Chairman

Mr. Klemp serves as the Executive Chairman of Autonomix Medical. He provides high-level strategic guidance and leadership to the Board of Directors and the executive management team. The company's leadership team indicates that the Resonic cellulite treatment was launched by their CEO, CFO, and Executive Chairman and purchased by AbbVie in 2021.

Dr. Robert Schwartz Chief Medical Officer

Dr. Schwartz is a Co-Founder of Autonomix Medical and has served as Chief Medical Officer since June 2023, and previously as Chief Executive Officer from February 2022 until June 2023. He is a serial medical device inventor and developer of the Watchman™ cardiology device, a left atrial appendage closure device that was sold to Boston Scientific in 2011 and has generated over $1 Billion in revenue.

Landy Toth Chief Technology Officer

Mr. Toth is a Co-Founder of Autonomix, co-founding the company in August 2014 and serving as Chief Technology Officer since that time. He is a mechanical engineer and medical device expert, and a key inventor responsible for Autonomix's development efforts to date. He founded Tricord Holdings, LLC in 2012 and founded and served as Chief Technology Officer of LifeLens Technologies, Inc. since September 2016. Over the past 20 years, Mr. Toth has successfully commercialized medical device technologies within startup environments.

Key Risks for Autonomix Medical (AMIX):

1. Clinical Trial and Regulatory Approval Risk: As a development stage company, there is no guarantee that Autonomix Medical's clinical trials will produce positive results or support their claims. The ability to successfully recreate promising animal study results in human clinical trials and subsequently obtain the necessary regulatory clearance for commercial use is a fundamental risk to the business.
2. Manufacturing and Commercial Scale-Up Risk: Autonomix Medical faces a significant challenge in scaling up from its existing hand-built prototype to a robust commercial version of its sensing device. The company has not yet assembled or tested the commercial version, and there is no assurance that they will be able to successfully build the device on a commercial scale, even if it is cleared for commercial use.

Autonomix Medical (AMIX) operates in several addressable markets related to sensing and treating disorders of the nervous system. The company's technology has potential applications in various areas, with the following estimated market sizes:

• Pancreatic Cancer Pain Management: The global pancreatic cancer treatment market, which includes pain management, was estimated at approximately USD 2.92 billion in 2024 and is projected to reach USD 5.84 billion by 2030, growing at a CAGR of 12.3% from 2025 to 2030. Another estimate values the global market at USD 3.82 billion in 2025, with a projected growth to USD 14.43 billion by 2034. North America dominated this market, holding a global share of 39.27% in 2024.
• Pancreatitis Pain Management: The global chronic pancreatitis pain market was approximately USD 9.67 billion in 2023 and is predicted to reach about USD 16.05 billion by 2032. North America was the leading segment for chronic pancreatitis pain in 2023. For acute pancreatitis, the global market size was valued at USD 6.14 billion in 2024 and is poised to grow to USD 10.29 billion by 2033. North America held the largest global market share of 42.7% in 2024 for acute pancreatitis.
• Chronic Pain Management (all causes): The global chronic pain treatment market was valued at USD 78.0 billion in 2024 and is projected to reach USD 155.2 billion by 2035. Other estimates for the global chronic pain treatment market include USD 90.73 billion in 2024, anticipated to reach USD 152.42 billion by 2032. North America accounted for the largest market share, at 45% in 2024.
• Hypertension Management: The global hypertension management devices market was valued at USD 4.34 billion in 2023 and is expected to reach nearly USD 13.22 billion by 2030. North America dominates the hypertension management devices market. The global blood pressure monitoring devices market size was estimated at USD 4.19 billion in 2025 and is expected to reach USD 8.56 billion by 2033.
• Cardiovascular Disease Treatment: The global cardiovascular treatment market size was estimated at USD 241.18 billion in 2024 and is projected to reach USD 383.11 billion by 2033. North America held the largest revenue share in the global cardiovascular treatment market in 2024, at 35.95%. The global cardiovascular drugs market size is valued at USD 155.96 billion in 2025 and is expected to reach around USD 214.72 billion by 2034.

1. Successful completion of pivotal clinical trials and regulatory approval: Autonomix Medical's primary driver of future revenue growth hinges on the successful completion of its ongoing and planned clinical trials, particularly the "POC 2" market expansion study, which is expected to begin in Q2 2025, and a planned multicenter U.S. clinical trial in 2026. These trials aim to validate the efficacy and safety of its nerve-targeted transvascular energy delivery technology, initially for pancreatic cancer pain management, leading to crucial regulatory approvals for commercialization.
2. Commercial launch and market penetration for initial indications: Following regulatory clearance, the successful commercial launch and widespread adoption of their device for severe pancreatic cancer pain will be a significant revenue driver. The positive results from the "POC 1" trial, demonstrating rapid and sustained pain relief and opioid-free outcomes, support the potential for strong market acceptance upon availability.
3. Expansion of approved indications to additional disease states: Beyond pancreatic cancer pain, Autonomix Medical's technology platform has broad potential to address dozens of indications. The company's "POC 2" trial is designed to expand beyond pancreatic cancer pain to include other visceral cancers such as gallbladder, liver, and bile duct cancers, as well as earlier-stage pancreatic cancers. Further expansion into chronic pain management, hypertension, and cardiovascular disease, as highlighted in their platform potential, will open up substantial new revenue streams.
4. Scaling of manufacturing and distribution capabilities: As a development-stage company with a currently hand-built sensing prototype, scaling up to a robust commercial version is a critical driver for revenue growth. The ability to efficiently manufacture and distribute its catheter-based microchip-enabled array at commercial volumes will be essential to meet market demand and translate clinical success into significant sales.
5. Strategic partnerships and collaborations for market acceleration: To expedite market entry and broaden reach, Autonomix Medical's ability to forge strategic partnerships and collaborations will be vital. These partnerships could provide necessary funding, expertise in large-scale manufacturing, and established distribution channels, accelerating the commercialization timeline and amplifying revenue generation. The company's engagement in investor conferences, such as LSI USA '26, facilitates such potential collaborations.

Share Issuance

• Autonomix Medical completed its initial public offering (IPO) on January 29, 2024, raising gross proceeds of $11.2 million and net proceeds of $9.8 million through the sale of 2,234,222 shares of common stock at $5.00 per share.
• The company closed an equity offering in November 2024, which generated approximately $10.0 million in gross proceeds (about $9.0 million net cash proceeds).
• Through an at-the-market (ATM) program, Autonomix Medical sold 1,304,260 shares for net proceeds of approximately $2.1 million through June 30, 2025.

Outbound Investments

• On July 10, 2024, Autonomix Medical entered into a license agreement with RF Innovations, Inc. (RFI) to license products utilizing RFI's intellectual property related to its Apex 6 Radiofrequency Generator.

Capital Expenditures

• In the last 12 months (as of March 06, 2026), Autonomix Medical's capital expenditures were -$11,000.
• For Q4 2026, Autonomix Medical invested $7 in capital expenditures.
• As of Q4 2026, the company reported $20,000 in Property, Plant & Equipment - Net.